US 12,220,445 B2
Inert matrices for qualitative and semi-quantitative seed amplification assays
Luis Concha, San Diego, CA (US); Carly Farris, San Diego, CA (US); Yihua Ma, Corona, CA (US); and Hieu Huu Nguyen, San Diego, CA (US)
Assigned to Amprion, Inc., San Francisco, CA (US)
Filed by Amprion, Inc., San Francisco, CA (US)
Filed on Sep. 9, 2022, as Appl. No. 17/931,104.
Application 17/931,104 is a continuation in part of application No. PCT/US2021/021441, filed on Mar. 9, 2021.
Claims priority of provisional application 63/328,443, filed on Apr. 7, 2022.
Claims priority of provisional application 63/243,470, filed on Sep. 13, 2021.
Claims priority of provisional application 62/986,921, filed on Mar. 9, 2020.
Prior Publication US 2023/0084155 A1, Mar. 16, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 31/185 (2006.01); A61K 38/17 (2006.01); A61K 38/38 (2006.01); A61K 39/395 (2006.01); A61P 1/00 (2006.01); A61P 1/04 (2006.01); A61P 25/00 (2006.01); A61P 25/02 (2006.01)
CPC A61K 38/385 (2013.01) [A61K 31/185 (2013.01); A61K 38/1774 (2013.01)] 15 Claims
 
1. A composition, consisting essentially of:
(A)
human serum albumin (HSA);
(B) aqueous NaCl; and
(C) (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES),
wherein the composition is inert relative to a monomeric alpha-synuclein protein and to a fluorescent protein aggregation indicator.